$HBIO

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

Benchmark raised its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00 and kept a Speculative Buy rating after Q2 results. Q2 revenue was $22.7M, above guidance and consensus. Full-year 2026 revenue growth guidance was lifted to 3% to 5%. Adjusted gross margin target was lowered to 57% to 59%.

Harvard Bioscience (HBIO) reported Q2 revenue of $22.7 million, up 11% year over year, with gross profit $12.6 million and gross margin 55.6%. Adjusted EBITDA rose to $1.7 million. The company raised FY2026 revenue growth guidance to 3%-5% and expects Q3 2026 revenue of $21.0 million to $22.6 million.

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2026 Financial Results · Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million · Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass.,

The article reports on the discontinued operations of Harvard Bioscience, Inc., traded on the Frankfurt Stock Exchange under the symbol HBI0. It appears to be a financial news brief, likely indicating a change in the company's operational status. The content is brief and serves as a notification regarding this financial event.

HOLLISTON, Mass., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. HBIO ( the "Company" or "Harvard Bioscience" ) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board's Nominating and ...

HOLLISTON, Mass., June 02, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. HBIO ( the "Company" ) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees.

HOLLISTON, Mass., June 02, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. ( Nasdaq: HBIO ) ( the "Company" ) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees.

HOLLISTON, Mass., May 05, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. ( Nasdaq: HBIO ) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.